CABA
Cabaletta Bio Inc

3,328
Mkt Cap
$215.63M
Volume
3.12M
52W High
$5.46
52W Low
$0.9857
PE Ratio
-0.89
CABA Fundamentals
Price
$2.15
Prev Close
$2.24
Open
$2.29
50D MA
$2.47
Beta
1.66
Avg. Volume
6.23M
EPS (Annual)
-$2.34
P/B
1.55
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Rating of "Moderate Buy" from Analysts
Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven brokerages that are currently covering the company, Marketbeat Ratings reports...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Analysts Set Expectations for Cabaletta Bio FY2025 Earnings
Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of Cabaletta Bio in a note issued to investors on Tuesday, November...
MarketBeat·6d ago
News Placeholder
FY2025 EPS Estimate for Cabaletta Bio Decreased by Analyst
Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Analysts at HC Wainwright lowered their FY2025 earnings estimates for shares of Cabaletta Bio in a report released on Tuesday, November 11th. HC...
MarketBeat·6d ago
News Placeholder
Cabaletta Bio FY2025 EPS Estimate Increased by William Blair
Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Research analysts at William Blair upped their FY2025 EPS estimates for Cabaletta Bio in a research report issued on Monday, November 10th. William...
MarketBeat·6d ago
News Placeholder
Cabaletta Bio (NASDAQ:CABA) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS
Cabaletta Bio (NASDAQ:CABA - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of...
MarketBeat·9d ago
News Placeholder
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Zacks·16d ago
News Placeholder
Why Does Cantor Fitzgerald See Over 1,000% Potential Upside For Cabaletta Bio Stock?
The analyst noted that Auto-CAR-T is showing unprecedented and transformational efficacy in systemic sclerosis, and investors aren't appreciating the substantial unmet need this represents.
Stocktwits·20d ago
News Placeholder
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
Cabaletta Bio (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·3mo ago
News Placeholder
Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased
The company announced the addition of two subtype-specific cohorts to its RESET-Myositis trial and received RMAT designation from the FDA for rese-cel.
Stocktwits·6mo ago
News Placeholder
Buy Rating Affirmed for Cabaletta Bio Amid Superior CD19 CAR T Therapy Efficacy in Autoimmune Disease Treatment
Wells Fargo analyst Derek Archila maintained a Buy rating on Cabaletta Bio (CABA Research Report) yesterday and set a price target of $20.00. Der...
TipRanks Financial Blog·1y ago

Latest CABA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.